Final results from the ribavirin pregnancy registry, 2004–2020
Sign Up to like & getrecommendations! Published in 2022 at "Birth Defects Research"
DOI: 10.1002/bdr2.2094
Abstract: Introduction: Significant teratogenic effects have been demonstrated for ribavirin in animal studies. Ribavirin is prescribed for chronic hepatitis C and is contraindicated in pregnant women and their male sexual partners. Both are advised to avoid… read more here.
Keywords: ribavirin pregnancy; 2004 2020; registry; pregnancy ... See more keywords
Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33556
Abstract: Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single‐agent activity with manageable toxicity… read more here.
Keywords: renal cell; inhibitor; final results; advanced renal ... See more keywords
Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
Sign Up to like & getrecommendations! Published in 2017 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-017-3681-2
Abstract: Dear Editor: We would to address several challenges that have arisen from the study by Chatziralli et al. [1], which can be specifically summarized below. Several relevant data are missing from the study (Table 1).… read more here.
Keywords: study; final results; etdrs letters; aflibercept ... See more keywords
Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV‐CHEP) for the treatment of aggressive adult T‐cell leukaemia/lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Haematology"
DOI: 10.1111/bjh.20177
Abstract: with other commonly used regimens. Because of the rarity of this disease, this effort will require incredible international coordination between sites in the United States, Latin America, Europe and Japan. Additionally, newer immunotherapies and targeted… read more here.
Keywords: multicentre pilot; evaluating brentuximab; pilot study; study evaluating ... See more keywords
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemo-radiation in stage III NSCLC. SLCG 10/02.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e20521
Abstract: e20521Background: This study aims to compare efficacy and safety of two widely used combinations of cisplatin (P) in this setting: as etoposide (E) and vinorelbine. This last, in its oral formulati... read more here.
Keywords: vinorelbine; final results; randomized phase; results reno ... See more keywords
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4106
Abstract: 4106 Background: Approved systemic therapies for advanced NETs have showed limited tumor shrinkage and no data of activity after progression to prior targeted agents (TA) is available. Lenvatinib, a potent VEGFR1-3 & FGFR1-4 inhibitor may… read more here.
Keywords: final results; radiology; pfs; talent trial ... See more keywords